Does NAFLD Fibrosis Score predict mortality risk among MAFLD patients?: a systematic review and meta-analysis

摘要

Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD) is a prevalent liver disease affecting 1 million people and projected to be the leading cause of liver transplantation in 2030 due to its progression of liver fibrosis. Several non-invasive scoring systems have been established to predict advanced fibrosis among MAFLD patients, namely NAFLD Fibrosis Score (NFS). Whether its performance remains useful in determining mortality risk in the MAFLD population is less clear. This study was aimed to assess the usefulness of NFS to predict mortality risk among MAFLD patients.